GSK, Pfizer RSV Shots Must Warn About Rare Paralysis Risk

 

GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can lead to paralysis, the US Food and Drug Administration said.

A study done after the respiratory syncytial virus shots were approved suggests that people given GSK’s Arexvy and Pfizer’s Abrysvo may be at increased risk of Guillain-Barré syndrome for 42 days following immunization, the agency said in a safety communication issued Tuesday.

https://www.bloomberg.com/news/articles/2025-01-07/gsk-pfizer-rsv-shots-to-warn-about-rare-neurological-disorder